Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688488'
s EV-to-EBIT Range Over the Past 10 Years
Min: -156.33 Med: -30.29 Max: 371.72
Current: 153.87
During the past 10 years, the highest EV-to-EBIT of Jiangsu Aidea Pharmaceutical Group Co was 371.72. The lowest was -156.33. And the median was -30.29.
SHSE:688488's EV-to-EBIT is ranked worse than 95.65% of 368
companies
in the Biotechnology industry
Industry Median: 15.545
vs SHSE:688488: 153.87
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jiangsu Aidea Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥5,727.5 Mil.
Jiangsu Aidea Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBIT Related Terms
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBIT Chart
SHSE:688488 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBIT vs Biotechnology Industry
Jiangsu Aidea Pharmaceutical Group Co's current Enterprise Value is ¥6,930.9 Mil.
Jiangsu Aidea Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) has a EV-to-EBIT of 153.87 as of Sep. 04, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jiangsu Aidea Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #352 out of 368 companies in the Biotechnology industry, placing it in the top 95.7%.
Is Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBIT too high?
Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBIT is 153.87. The Biotechnology industry median EV-to-EBIT is 15.55. Jiangsu Aidea Pharmaceutical Group Co's value of 153.87 is 889.8% above this industry median. Based on the distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #352 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Aidea Pharmaceutical Group Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #352 out of 368 companies for EV-to-EBIT. This places Jiangsu Aidea Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBIT is 15.55. Jiangsu Aidea Pharmaceutical Group Co's value of 153.87 is 889.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBIT of 153.87 is 889.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jiangsu Aidea Pharmaceutical Group Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBIT is 153.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Aidea Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥19.30, compared to a current price of ¥15.44 — trading 20% below its estimated fair value. The current EV-to-EBIT is 153.87 and 889.8% above the Biotechnology industry median of 15.55. Jiangsu Aidea Pharmaceutical Group Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488), the current EV-to-EBIT is 153.87 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥15.44 is trading 20% below its estimated GF Value™ of ¥19.30.
GuruFocus considers Jiangsu Aidea Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:688488:
EV-to-EBIT: 153.87
GF Value™: ¥19.30 vs. price of ¥15.44 (20% below fair value)
Industry Position: 889.8% above the Biotechnology median (#352 of 368)
No single metric tells the full story. See the SHSE:688488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Aidea Pharmaceutical Group Co Ltd is engaged in the production and sales of human protein products, and also carries out some generic drug business and distributes Abbott's HIV diagnostic equipment and reagents.
74GF Score
Get the complete analysis for SHSE:688488
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688488 has been successfully added to your 
